請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66498完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 周綠蘋 | |
| dc.contributor.author | Yi-An Hsueh | en |
| dc.contributor.author | 薛宜安 | zh_TW |
| dc.date.accessioned | 2021-06-17T00:39:10Z | - |
| dc.date.available | 2014-03-02 | |
| dc.date.copyright | 2012-03-02 | |
| dc.date.issued | 2012 | |
| dc.date.submitted | 2012-01-30 | |
| dc.identifier.citation | 1. Polk, D. B. and R. M. Peek, Jr. (2010). 'Helicobacter pylori: gastric cancer and beyond.' Nat Rev Cancer 10(6): 403-414.
2. Herszenyi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 2010; 14: 249-258 3. Herrera V, Parsonnet J. Helicobacter pylori and gastric adenocarcinoma. Clin Microbiol Infect 2009; 15: 971-976 4. Peek, R. M., Jr. and M. J. Blaser (2002). 'Helicobacter pylori and gastrointestinal tract adenocarcinomas.' Nat Rev Cancer 2(1): 28-37 5. Ricci, V., M. Romano, et al. (2011). 'Molecular cross-talk between Helicobacter pylori and human gastric mucosa.' World J Gastroenterol 17(11): 1383-1399. 6. Chia-Hsin Chan, Chia-Cheng Ko, Jan-Gowth Chang, Sung-Fang Chen, Ming-Shiang Wu, Jaw-Town Lin, and Lu-Ping Chow Molecular & Cellular Proteomics 2006: 702-713 7. Braun, R. J. and H. Zischka (2008). 'Mechanisms of Cdc48/VCP-mediated cell death: from yeast apoptosis to human disease.' Biochim Biophys Acta 1783(7): 1418-1435. 8. T. Shirogane, T. Fukada, J.M. Muller, D.T. Shima, M. Hibi, T. Hirano, Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis, Immunity 11 (1999) 709–719. 9. T. Asai, Y. Tomita, S. Nakatsuka, Y. Hoshida, A. Myoui, H. Yoshikawa, K. Aozasa, VCP (p97) regulates NF-kappaB signaling pathway, which is important for metastasis of osteosarcoma cell line, Jpn. J. Cancer Res. 93 (2002) 296–304. 10. C.H. Chan, C.C. Ko, J.G. Chang, S.F. Chen, M.S. Wu, J.T. Lin, L.P. Chow, Subcellular and functional proteomic analysis of the cellular responses induced by Helicobacter pylori, Mol. Cell. Proteomics 5 (2006) 702–713. 11. Y. Tsujimoto, Y. Tomita, Y. Hoshida, T. Kono, T. Oka, S. Yamamoto, N. Nonomura, A. Okuyama, K. Aozasa, Elevated expression of valosincontaining protein (p97) is associated with poor prognosis of prostate cancer, Clin. Cancer Res. 10 (2004) 3007–3012. 12. S. Yamamoto, Y. Tomita, Y. Hoshida, N. Iizuka, S. Kidogami, H. Miyata, S. Takiguchi, Y. Fujiwara, T. Yasuda, M. Yano, S. Nakamori, M. Sakon, M. Monden, K. Aozasa, Expression level of valosin-containing protein (p97) is associated with prognosis of esophageal carcinoma, Clin. Cancer Res. 10 (2004) 5558–5565. 13. S. Yamamoto, Y. Tomita, Y. Hoshida, N. Iizuka, M. Monden, S. Yamamoto, K. Iuchi, K. Aozasa, Expression level of valosin-containing protein (p97) is correlated with progression and prognosis of non-small-cell lung carcinoma, Ann. Surg. Oncol. 11 (2004) 697–704. 14. S. Yamamoto, Y. Tomita, Y. Hoshida, H. Nagano, K. Dono, K. Umeshita, M. Sakon, O. Ishikawa, H. Ohigashi, S.Nakamori, M.Monden, K. Aozasa, Increased expression of valosin-containing protein (p97) is associated with lymph node metastasis and prognosis of pancreatic ductal adenocarcinoma, Ann. Surg. Oncol. 11 (2004) 165–172. 15. S. Yamamoto, Y. Tomita, Y. Hoshida, M. Sakon, M. Kameyama, S. Imaoka, M. Sekimoto, S. Nakamori, M. Monden, K. Aozasa, Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis, Clin. Cancer Res. 10 (2004) 651–657. 16. S. Yamamoto, Y. Tomita, Y. Hoshida, S. Takiguchi, Y. Fujiwara, T. Yasuda, M. Yano, S. Nakamori, M. Sakon, M. Monden, K. Aozasa, Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastric carcinoma, J. Clin. Oncol. 21 (2003) 2537–2544. 17. S. Yamamoto, Y. Tomita, Y. Hoshida, S. Toyosawa, H. Inohara, M. Kishino, M. Kogo, M. Nakazawa, S. Murakami, N. Iizuka, S. Kidogami, M. Monden, T. Kubo, N. Ijuhin, K. Aozasa, Expression level of valosincontaining protein (VCP) as a prognostic marker for gingival squamous cell carcinoma, Ann. Oncol. 15 (2004) 1432–1438. 18. S. Yamamoto, Y. Tomita, S. Nakamori, Y. Hoshida, N. Iizuka, J. Okami, H. Nagano, K. Dono, K. Umeshita, M. Sakon, O. Ishikawa, H. Ohigashi, K. Aozasa, M. Monden, Valosin-containing protein (p97) and Ki-67 expression is a useful marker in detecting malignant behavior of pancreatic endocrine neoplasms, Oncology 66 (2004) 468–475. 19. S. Yamamoto, Y. Tomita, S. Nakamori, Y. Hoshida, H. Nagano, K. Dono, K. Umeshita, M. Sakon, M. Monden, K. Aozasa, Elevated expression of valosin-containing protein (p97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence, J. Clin. Oncol. 21 (2003) 447–452. 20. S. Yamamoto, Y. Tomita, T. Uruno, Y. Hoshida, Y. Qiu, N. Iizuka, I. Nakamichi, A. Miyauchi, K. Aozasa, Increased expression of valosincontaining protein (p97) is correlated with disease recurrence in follicular thyroid cancer, Ann. Surg. Oncol. 12 (2005) 925–934. 21. S. Asaka, T. Fujimoto, J. Akaishi, K. Ogawa, M. Onda, Genetic prognostic index influences patient outcome for node-positive breast cancer, Surg. Today 36 (2006) 793–801. 22. M. Lauten, A. Schrauder, C. Kardinal, J. Harbott, K. Welte, B. Schlegelberger, M. Schrappe, N. von Neuhoff, Unsupervised proteome analysis of human leukaemia cells identifies the Valosin-containing protein as a putative marker for glucocorticoid resistance, Leukemia 20 (2006) 820–826. 23. C.H. Zhao, Q.F. Li, Altered profiles of nuclear matrix proteins during the differentiation of human gastric mucous adenocarcinoma MGc80-3 cells, World J. Gastroenterol. 11 (2005) 4628–4633. 24. F. Vandermoere, I. El Yazidi-Belkoura, C. Slomianny, Y. Demont, G. Bidaux, E. Adriaenssens, J. Lemoine, H. Hondermarck, The valosincontaining protein (VCP) is a target of Akt signaling required for cell survival, J. Biol. Chem. 281 (2006) 14307–14313. 25. Frohlich, K. U., Fries, H. W., Rudiger, M., Erdmann, R., Botstein, D., and Mecke, D. (1991) J Cell Biol 114, 443-453 26. Pamnani, V., Tamura, T., Lupas, A., Peters, J., Cejka, Z., Ashraf, W. and Baumeister, W. (1997) FEBS Lett, 263-268 27. Peters, J. M., Walsh, M.J. and Franke, W.W. (1990) Embo J, 9, 1757-1767. 28. Neuwald, A. F., Aravind, L., Spouge, J.L. and Koonin, E.V (1999) Genome Res, 9, 27-43. 29. Wang, Q., C. Song, et al. (2004). 'Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions.' J Struct Biol 146(1-2): 44-57. 30. Yamanaka, K., Y. Sasagawa, et al. (2011). 'Recent advances in p97/VCP/Cdc48 cellular functions.' Biochim Biophys Acta. 31. Dai, R. M. a. L., C.C. . (2001) Nat Cell Biol 3, 740-744. 32. Kondo, H., Rabouille, C., Newman, R., Levine, T.P., Pappin, D., Freemont, P. and Warren, G. (1997) Nature 388, 75-78 33. Rothman, J. E. a. W., G. (1994) Curr Biol 4, 220-233. 34. Rabouille, C., Kondo, H., Newman, R., Hui, N., Freemont, P. and Warren, G. . (1998) Cell 92, 603-610. 35. Bernasconi, R. and M. Molinari (2011). 'ERAD and ERAD tuning: disposal of cargo and of ERAD regulators from the mammalian ER.' Curr Opin Cell Biol 23(2): 176-183. 36. Lim, P. J., R. Danner, et al. (2009). 'Ubiquilin and p97/VCP bind erasin, forming a complex involved in ERAD.' J Cell Biol 187(2): 201-217. 37. Ghosh, S., May, M.J. and Kopp, E.B. (1998) Annu Rev Immunol, 225-260 38. Nakayama, K. I. a. N., K. . (2006 ) Nat Rev Cancer 369-381 39. Wu, D., Chen, P.J., Chen, S., Hu, Y., Nunez, G. and Ellis, R.E. . (1999 ) Development, 2021-2031 40. Cezary Wójcik, Mihiro Yano, and George N. DeMartino, (2004) Journal of Cell Science 117: 281-292 41. Polk, D. B. and R. M. Peek, Jr. (2010). 'Helicobacter pylori: gastric cancer and beyond.' Nat Rev Cancer 10(6): 403-414. 42. Maciorkowska, E., K. Guzinska-Ustymowicz, et al. (2009). 'The EGFR expression in gastric mucosa of children infected with Helicobacter pylori.' Adv Med Sci 54(2): 187-193. 43. Poksay, K. S., D. T. Madden, et al. (2011). 'Valosin-containing protein gene mutations: cellular phenotypes relevant to neurodegeneration.' J Mol Neurosci 44(2): 91-102. 44. Vandermoere, F., I. El Yazidi-Belkoura, et al. (2006). 'The valosin-containing protein (VCP) is a target of Akt signaling required for cell survival.' J Biol Chem 281(20): 14307-14313. 45. Abbas, T. and A. Dutta (2009). 'p21 in cancer: intricate networks and multiple activities.' Nat Rev Cancer 9(6): 400-414. 46. Carter, S., O. Bischof, et al. (2007). 'C-terminal modifications regulate MDM2 dissociation and nuclear export of p53.' Nat Cell Biol 9(4): 428-435. 47. Fueller, J., M. Becker, et al. (2008). 'C-RAF activation promotes BAD poly-ubiquitylation and turn-over by the proteasome.' Biochem Biophys Res Commun 370(4): 552-556. 48. Morizane, Y., R. Honda, et al. (2005). 'X-linked inhibitor of apoptosis functions as ubiquitin ligase toward mature caspase-9 and cytosolic Smac/DIABLO.' J Biochem 137(2): 125-132. 49. Stapf, C., E. Cartwright, et al. (2011). 'The general definition of the p97/valosin-containing protein (VCP)-interacting motif (VIM) delineates a new family of p97 cofactors.' J Biol Chem 286(44): 38670-38678. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66498 | - |
| dc.description.abstract | 幽門螺旋桿菌係是導致胃癌之重要因子,雖然因幽門螺旋桿菌所導致胃癌的關聯性早已建立,但由幽門螺旋桿菌所造成胃癌的分子機制尚未明確。先前,本實驗室利用免疫沉澱及蛋白質體學的方式,發現當幽門螺旋桿菌感染胃腺癌上皮細胞(AGS)時,有許多與癌症相關的蛋白質表現量亦為提高。其中以缬絡胺酸蛋白質(Valosin-containing protein)的表現差異特別顯著,此結果與病理組織切片染色觀察到缬絡胺酸蛋白質表現量的上升亦有符合。本實驗目的是探討當幽門螺旋桿菌感染胃腺癌上皮細胞時,缬絡胺酸蛋白質在其中所扮演的角色,並且分析這些與缬絡胺酸蛋白質有交互作用的蛋白質。在當幽門螺旋桿菌感染細胞後,經免疫沉澱及蛋白質體學的實驗下,我們鑑定到了176個與缬絡胺酸蛋白質有交互作用的蛋白,我們併用生物資訊軟體(IPA)分析。分析結果顯示,與缬絡胺酸蛋白質有交互作用的蛋白建構成一個網路,這個網絡與細胞存活、細胞增生、癌症生成,等生理作用有關。更進一步分析,此網絡與絲氨酸/蘇氨酸激酶(AKT singaling)信息傳遞,有高度的關聯。我們更進一步在實驗中發現當幽門螺旋桿菌感染胃腺癌上皮細胞時,絲氨酸/蘇氨酸激酶會被磷酸化,活化後的絲氨酸/蘇氨酸激酶會磷酸化缬絡胺酸蛋白質,缬絡胺酸蛋白質的磷酸化,會促使促細胞凋亡分因子、細胞週期抑制蛋白的降解。藉由共軛焦螢光顯微鏡的觀察,幽門螺旋桿菌感染胃腺癌上皮細胞時,經泛素修飾蛋白質與缬絡胺酸蛋白質形成聚集體,此行為促使凋亡因子及細胞週期抑制蛋白的降解,進而造成細胞的存活及癌化。 | zh_TW |
| dc.description.abstract | Helicobacter pylori is an important risk factor of gastric cancer. Although many H. pylori virulence factors have been reported, the pathogenic mechanism by which H. pylori infection causes gastric cancer remains unclear. Previously, by using proteomics approaches and immunohistochemistry, we found that the protein expression level of many cancer-related factors were elevated in AGS cells after H. pylori infection, and one important factor was valosin-containing protein (VCP). By identification the interactome of over-expressed VCP in AGS cells through a proteomics approach, we aimed to characterize the cellular responses mediated by VCP and its functional roles in H. pylori-associated gastric cancer. 176 interacting proteins were identified through via approach, and with the assistance of IPA analysis to search for significantly enriched signaling pathways, we focused on proteins involved in cell survival, proliferation and cancer development among these candidates. We found AKT as a key interacting protein of VCP in H. pylori-induced gastric cancer. We observed that H. pylori infection enhances the interaction between AKT and VCP, and also an AKT-dependent phosphorylation of VCP in AGS cells. Interestingly, the AKT-dependent VCP phosphorylation protects AGS cells from apoptosis, which is governed by phosphotidylinositol 3-kinase (PI3K) and also degradation of apoptotic factor or cell cycle inhibitor. Confocal microscopy indicated a co-localization between VCP and ubiquitinated cell regulators upon AKT stimulation. In addition, our current data indicated that VCP may involve in aggresome formation, possibly for their ubiquitinated protein degradation. Together, these data identified VCP as an important target in the AKT-mediated signaling of cell survival. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T00:39:10Z (GMT). No. of bitstreams: 1 ntu-101-R98442020-1.pdf: 3212563 bytes, checksum: 03ebb0294f3a1246a30ca4b0e79c5d11 (MD5) Previous issue date: 2012 | en |
| dc.description.tableofcontents | 第一章 導論----------8
1. 簡述 1.1 幽門螺旋桿菌(Helicobacter pylori )與癌症的關聯性 1.2 VCP蛋白與癌症之研究 2. VCP蛋白的結構 3. VCP蛋白的功能 3.1 蛋白質經泛素修飾後之降解反應 3.2 膜的融合 3.3 內質網參與的蛋白質降解 3.4 轉錄因子活化 3.5 細胞週期調控 3.6 細胞凋亡之抑制 3.7 伴護蛋白之角色 4. VCP蛋白與聚集體(aggresome)的關係 5. VCP蛋白在細胞存活所扮演的角色 6. VCP蛋白在泛素-26S蛋白酶降解系統參與之功能 7. 實驗目的 第二章 實驗材料----------19 1. 幽門螺旋桿菌菌株 2. 胃腺癌上皮細胞 3. 儀器及裝置 4. 酵素 5. 抗體 6. 試劑組與藥品 7. 軟體及資料庫 第三章 實驗方法----------23 1. 幽門螺旋桿菌的培養 2. 細胞培養液配置 3. 胃腺癌上皮細胞(AGS)培養 4. 細胞記數 5. 幽門螺旋桿菌的收取 6. 細胞的準備及感染幽門螺旋桿菌 7. 蛋白質濃度測定 (BCA protein assay) 8. 十二烷基磺酸鈉-聚丙烯醯胺膠體電泳分析 (SDS-PAGE) 9. 西方墨點法 (Western blotting) 10. 質體轉染 (Transfection) 11. IPA軟體分析(Ingenuity Pathway Analysis) 12. 免疫螢光玻片染色觀察 第四章 實驗結果----------32 1. 利用IPA來統整分析與VCP蛋白有交互作用之蛋白質 2. IPA分析結果,與VCP有交互作用之蛋白在細胞功能上的角色 3. 分子參與之信息傳遞路徑 4. VCP蛋白與經泛素修飾蛋白在細胞內的分布情形 5. 利用電子顯微鏡(TEM),觀察聚集體的形成 6. VCP蛋白的磷酸化將導致泛素聚集體的產生 7. 幽門螺旋桿菌感染胃腺癌上皮細胞下,VCP蛋白扮演抑制細胞凋亡之功能 第五章 討論----------37 1. 幽門螺旋桿菌所扮演的角色 2. 聚集體生成的生理功能 3. VCP蛋白交互作用之標的 4. VCP交互作用之蛋白在細胞內主要的影響 5. VCP蛋白受質之專一性的選擇 6. 幽門螺旋桿菌引起磷酸化之重要性 7. 未來方向 第六章 圖表與說明----------44 第七章 參考文獻----------58 附錄----------64 | |
| dc.language.iso | zh-TW | |
| dc.subject | 胃癌 | zh_TW |
| dc.subject | 纈絡胺酸 | zh_TW |
| dc.subject | 免疫沉澱 | zh_TW |
| dc.subject | 交互作用體 | zh_TW |
| dc.subject | 訊息傳導 | zh_TW |
| dc.subject | gastric cancer | en |
| dc.subject | valosin-containing protein | en |
| dc.subject | immunoprecipitation | en |
| dc.subject | interactome | en |
| dc.subject | signal transduction | en |
| dc.title | 幽門螺旋桿菌感染之胃上皮細胞引起缬絡胺酸蛋白質的磷酸化及聚集體之形成並促進抗細胞凋亡之產生 | zh_TW |
| dc.title | Helicobactor pylori infection induces valosin-containing protein phosphorylation mediated aggresome formation and promotes antiapoptosis in gastric epithelial cell | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 100-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 陳美如,林琬琬,龔秀妮 | |
| dc.subject.keyword | 胃癌,纈絡胺酸,免疫沉澱,交互作用體,訊息傳導, | zh_TW |
| dc.subject.keyword | gastric cancer,valosin-containing protein,immunoprecipitation,interactome,signal transduction, | en |
| dc.relation.page | 73 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2012-01-30 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
| 顯示於系所單位: | 生物化學暨分子生物學科研究所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-101-1.pdf 未授權公開取用 | 3.14 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
